Diagnostic value of urine deoxypyridinoline for detecting bone metastases in breast cancer patients.
Deoxypyridinoline (Dpd), a crosslink product of collagen molecules found in bone and excreted in urine during bone degradation, has been described as a marker of bone turnover in metastatic breast cancer. In this study, the urine deoxypyridinoline/creatinine (Dpd/Cre) ratio was determined by enzyme immunoassay in urine samples from 116 women with breast cancer. Bone metastases were confirmed by x-ray or CT scan, with follow-up > 6 mo. The urine Dpd/Cre ratio was significantly higher in patients with bone metastasis, compared to those without bone metastasis (p < 0.05). In patients with bone metastasis, ratios of urine Dpd/Cre were higher in those with multiple lesions, compared to those with a solitary lesion, and the values also reflected therapeutic response (p < 0.05). Serial monitoring of urine Dpd/Cre revealed that an elevation was correlated with disease progression. Patients with stable bone disease under effective therapy had significant diminution of the urine Dpd/Cre ratios, compared to those with progression of bone disease (p < 0.05). In conclusion, the urine Dpd/Cre ratio may be a useful marker for detecting bone metastases and evaluating their response to therapy.
Hou
Ming-Feng
MF
Department of Surgery, Obstetrics and Gynecology, Kaohsiung Medical University, Taiwan, Republic of China.
Lin
Shwu-Bin
SB
Yuan
Shyng-Shiou F
SS
Tsai
Li-Yu
LY
Tsai
Shih-Meng
SM
Hsieh
Jan-Shih
JS
Huang
Tsung-Jen
TJ
D000328:Adult; D000368:Aged; D000596:Amino Acids / Q000652:urine*; D014408:Biomarkers, Tumor / Q000652:urine*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology*; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D011237:Predictive Value of Tests; D011786:Quality Control
D000596:Amino Acids; D014408:Biomarkers, Tumor; D004164:Diphosphonates; C036020:deoxypyridinoline